Comparison of treatment outcomes and safety of Lenvatinib versus sorafenib and to assess independent predictors of poor outcomes in Korean patients with unresectable Hepato Cellular Carcinoma
Latest Information Update: 27 Nov 2020
At a glance
- Drugs Lenvatinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- 27 Nov 2020 New trial record
- 20 Nov 2020 Primary endpoint, Overall Survival, has not been met as per results published in the Journal of Gastroenterology and Hepatology
- 20 Nov 2020 Results published in the Journal of Gastroenterology and Hepatology